Kyowa acquires Lonza production technology
This article was originally published in Scrip
Kyowa Hakko and its US antibody technology subsidiary BioWa have licensedLonza's glutamine synthetase (GS) gene expression system for use in the production of antibodies and recombinant proteins under development by the Japanese firm. The worldwide, non-exclusive deal adds to the basic research collaboration signed previously by the two firms to examine combining the GS system with BioWa's Potelligent antibody potency-enhancing technology. Kyowa will merge with Japan's Kirin Pharma in October to form Kyowa Hakko Kirin.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.